Literature DB >> 20804343

National perinatal audit, a feasible initiative for the Netherlands!? A validation study.

Mariet van Diem1, Paul De Reu, Martine Eskes, Hens Brouwers, Cas Holleboom, Tineke Slagter-Roukema, Hans Merkus.   

Abstract

OBJECTIVE: To explore the feasibility of a national perinatal audit organization.
DESIGN: Validation study.
SETTING: Three regions in the Netherlands. POPULATION: 228 cases of perinatal mortality.
METHODS: Narratives of perinatal mortality cases were assessed by a panel of representatives of all perinatal care provider groups. 123 cases were assessed twice. Consensus was defined as 75% agreement. For the chance corrected agreement Cohen's kappa statistic was used. MAIN OUTCOME MEASURES: Consensus and the chance corrected agreement on three cause of death classifications. The presence or absence of substandard factors (SSF) with the care provider, the organization of care and the relation of the SSF with perinatal death.
RESULTS: Consensus rates and chance corrected agreement for three cause of death classifications ranged from 92 to 96% and kappa 0.87 to kappa 0.93 (very good agreement), with comparable confidence intervals and similar values in the validation subset of 123 cases. On the presence of SSF at the level of the care provider consensus and chance corrected agreement was 68% and kappa 0.53 (moderate), with comparable values in the subset of 123 cases. Consensus for the relation between SSF at the level of the care provider and perinatal death was 81.4% and kappa 0.68 (good).
CONCLUSION: Perinatal audit on a national level with relatively large audit groups with many different care providers is feasible.

Entities:  

Mesh:

Year:  2010        PMID: 20804343     DOI: 10.3109/00016349.2010.500468

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  5 in total

1.  Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children.

Authors:  Cees C van den Wijngaard; Liselotte van Asten; Marion P G Koopmans; Wilfrid van Pelt; Nico J D Nagelkerke; Cornelia C H Wielders; Alies van Lier; Wim van der Hoek; Adam Meijer; Gé A Donker; Frederika Dijkstra; Carel Harmsen; Marianne A B van der Sande; Mirjam Kretzschmar
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

2.  Variation in referrals to secondary obstetrician-led care among primary midwifery care practices in the Netherlands: a nationwide cohort study.

Authors:  Pien M Offerhaus; Caroline Geerts; Ank de Jonge; Chantal W P M Hukkelhoven; Jos W R Twisk; Antoine L M Lagro-Janssen
Journal:  BMC Pregnancy Childbirth       Date:  2015-02-21       Impact factor: 3.007

Review 3.  Counting every stillbirth and neonatal death through mortality audit to improve quality of care for every pregnant woman and her baby.

Authors:  Kate J Kerber; Matthews Mathai; Gwyneth Lewis; Vicki Flenady; Jan Jaap H M Erwich; Tunde Segun; Patrick Aliganyira; Ali Abdelmegeid; Emma Allanson; Nathalie Roos; Natasha Rhoda; Joy E Lawn; Robert Pattinson
Journal:  BMC Pregnancy Childbirth       Date:  2015-09-11       Impact factor: 3.007

4.  Classification systems for causes of stillbirth and neonatal death, 2009-2014: an assessment of alignment with characteristics for an effective global system.

Authors:  Susannah Hopkins Leisher; Zheyi Teoh; Hanna Reinebrant; Emma Allanson; Hannah Blencowe; Jan Jaap Erwich; J Frederik Frøen; Jason Gardosi; Sanne Gordijn; A Metin Gülmezoglu; Alexander E P Heazell; Fleurisca Korteweg; Joy Lawn; Elizabeth M McClure; Robert Pattinson; Gordon C S Smith; Ӧzge Tunçalp; Aleena M Wojcieszek; Vicki Flenady
Journal:  BMC Pregnancy Childbirth       Date:  2016-09-15       Impact factor: 3.007

5.  Term perinatal mortality audit in the Netherlands 2010-2012: a population-based cohort study.

Authors:  Martine Eskes; Adja J M Waelput; Jan Jaap H M Erwich; Hens A A Brouwers; Anita C J Ravelli; Peter W Achterberg; Hans J M W M Merkus; Hein W Bruinse
Journal:  BMJ Open       Date:  2014-10-14       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.